XML 27 R16.htm IDEA: XBRL DOCUMENT v3.25.2
Revenue Recognition
 6 Months Ended
Jun. 30, 2025
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
Disaggregation of Revenues
The following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands):
 Three Months Ended
June 30, 2025		Three Months Ended
June 30, 2024
 U.S.Non U.S.TotalU.S.Non U.S.Total
Product revenue, net     
HEPLISAV-B$90,250 $1,622 $91,872 $68,988 $1,200 $70,188 
Total product revenue, net90,250 1,622 91,872 68,988 1,200 70,188 
Other revenue3,317 253 3,570 3,598 9 3,607 
Total revenues$93,567 $1,875 $95,442 $72,586 $1,209 $73,795 
Six Months Ended
June 30, 2025		Six Months Ended
June 30, 2024
U.S.Non U.S.TotalU.S.Non U.S.Total
Product revenue, net
HEPLISAV-B$155,209 $1,622 $156,831 $115,685 $2,347 $118,032 
Total product revenue, net155,209 1,622 156,831 115,685 2,347 118,032 
Other revenue6,164 611 6,775 6,400 152 6,552 
Total revenues$161,373 $2,233 $163,606 $122,085 $2,499 $124,584 
Revenues from Major Customers and Collaboration Partners
HEPLISAV-B product sales in the U.S. are to certain wholesalers and specialty distributors whose principal customers include integrated delivery networks, retail pharmacies, independent hospitals and clinics, public health clinics and prisons, the Department of Defense, and the Department of Veterans Affairs.
In May 2021, we entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV-B in Germany, and in May 2022, we commenced commercial shipments of HEPLISAV-B in Germany. In the second quarter of 2025, the commercialization agreement was not renewed. Bavarian Nordic will retain the distribution rights for HEPLISAV-B in Germany through April 2026, after which Dynavax will regain the commercialization rights. We do not currently market HEPLISAV-B outside the U.S.
The following table summarizes HEPLISAV-B product revenue from each of our three largest customers (as a percentage of total HEPLISAV-B net product revenue):
 Three Months Ended
June 30,		Six Months Ended
June 30,
 2025202420252024
Largest customer27%28%29%28%
Second largest customer20%22%20%21%
Third largest customer20%18%19%18%
Contract Balances
The following table summarizes balances and activities in HEPLISAV-B product revenue allowance and reserve categories for the six months ended June 30, 2025 (in thousands):
 
Balance at
Beginning
of Period
Provisions
related to
current
period sales
Credit or
payments
made during
the period
Adjustments (3)
Balance
at End of
Period
Six months ended June 30, 2025:
Accounts receivable reserves (1)
$9,317 $43,813 $(41,519)$(178)$11,433 
Revenue reserve accruals (2)
$31,479 $29,739 $(23,103)$(10,808)$27,307 
(1)Reserves are for chargebacks, discounts and other fees.
(2)Accruals are for returns, rebates and other fees.
(3)Adjustments for $10.8 million in connection to revenue reserve accruals primarily result from a change in estimate for product returns.
When we perform services under our agreement with the DoD, we recognize product revenue and a corresponding contract asset as our right to consideration is conditioned on something other than the passage of time. See Note 6 for further discussion. The following table summarizes balances and activities in our contract asset account (in thousands):
 
Balance at
Beginning
of Period
Additions
Subtractions
Balance
at End of
Period
Six months ended June 30, 2025
Contract asset, included in other current assets (1)
$351 $6,164 $(3,872)$2,643 
Contract asset, included in other assets (long term) (2)
$71,307 $— $(10,970)$60,337 
(1)The $2.6 million contract asset is derived from our agreement with the DoD.
(2)The Clover contract asset was included in non-current assets to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product. During the six months ended June 30, 2025, we recorded an allowance for doubtful accounts of approximately $11.0 million relating to the contract asset recognized for Clover. See Note 6 for further discussion.